Consensus on Clinical Application of the CXCR4-targeted Imaging in the Diagnosis of Primary Aldosteronism(2022)
Subtype classification of primary aldosteronism is important but challenging. Increasing evidence has shown that 68Ga-Pentixafor PET/CT imaging which targets CXCR4 is beneficial to the subtype classification of primary aldosteronism. Based on all the available evidence, and after in-depth discussion...
Main Authors: | Chinese Urological Doctor Association Adrenal Hypertension Surgery Collaborative Organization Adrenal Group, Chinese Society of Endocrinology PET group, Chinese Society of Nuclear Medicine |
---|---|
Format: | Article |
Language: | zho |
Published: |
Editorial Office of Medical Journal of Peking Union Medical College Hospital
2022-11-01
|
Series: | Xiehe Yixue Zazhi |
Subjects: | |
Online Access: | https://xhyxzz.pumch.cn/en/article/doi/10.12290/xhyxzz.2022-0584 |
Similar Items
-
A comparison of the performance of 68Ga-Pentixafor PET/CT versus adrenal vein sampling for subtype diagnosis in primary aldosteronism
by: Xuan Yin, et al.
Published: (2024-02-01) -
CXCR4-Directed Imaging in Solid Tumors
by: Rudolf A. Werner, et al.
Published: (2019-08-01) -
Automated synthesis and quality control of [68Ga]Ga-PentixaFor using the Gaia/Luna Elysia-Raytest module for CXCR4 PET imaging
by: Thomas Daniel, et al.
Published: (2023-02-01) -
Imaging Inflammation in Atherosclerosis with CXCR4-Directed [<sup>68</sup>Ga]PentixaFor PET/MRI—Compared with [<sup>18</sup>F]FDG PET/MRI
by: Xia Lu, et al.
Published: (2022-07-01) -
Current Status of <sup>68</sup>Ga-Pentixafor in Solid Tumours
by: Bawinile Hadebe, et al.
Published: (2022-09-01)